HVC
ALIM

Healthcare Value Capital’s Alimera Sciences ALIM Stock Holding History

Healthcare Value Capital’s Portfolio ALIM Stock Details ALIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-3,333
Closed -$251K – 39
2015
Q1 		$251K Hold
3,333
– – 0.27% 35
2014
Q4 		$277K Buy
+3,333
New +$270K 0.51% 24

Other funds holding ALIM

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SM
Scale Management Foster City, California $359M AUM
NRC
North Run Capital Boston, Massachusetts $43.5M AUM 38.24% 1-Year Est. Return
PVMCI
Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Healthcare Value Capital's ALIM Position: Q4 2015 in Review

Healthcare Value Capital sold out of Alimera Sciences (ALIM) in Q4 2015, closing a stake of 6,667 shares — an estimated $221K sold.

Healthcare Value Capital first reported a position in ALIM in Q4 2014 and held it in 4 quarters. The position peaked at $554K in Q4 2014. 66 funds tracked by Wall St. Rank hold ALIM as of Q4 2015.

  • Healthcare Value Capital reported no remaining Alimera Sciences position as of Q4 2015 after selling out during the quarter.
  • Healthcare Value Capital sold 6,667 Alimera Sciences shares in Q4 2015, an estimated $221K.
  • Healthcare Value Capital first reported a position in Alimera Sciences in Q4 2014 and held it in 4 quarters.
  • Healthcare Value Capital's Alimera Sciences position peaked at $554K in Q4 2014.
  • 66 funds tracked by Wall St. Rank held Alimera Sciences as of Q4 2015.

Based on Healthcare Value Capital's 13F filing for Q4 2015, filed 16 Feb 2016.